{
    "clinical_study": {
        "@rank": "107674", 
        "arm_group": [
            {
                "arm_group_label": "CJ-12420 Amg", 
                "arm_group_type": "Experimental", 
                "description": "50 volunteers will be administered CJ-12420 Amg"
            }, 
            {
                "arm_group_label": "CJ-12420 Bmg", 
                "arm_group_type": "Experimental", 
                "description": "50 volunteers will be administered CJ-12420 Bmg"
            }, 
            {
                "arm_group_label": "CJ-12420 Cmg", 
                "arm_group_type": "Experimental", 
                "description": "50 volunteers will be administered CJ-12420 Cmg"
            }, 
            {
                "arm_group_label": "Esomeprazole 40mg", 
                "arm_group_type": "Active Comparator", 
                "description": "50 volunteers will be administered Esomeprazole 40mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the optimal dose and administration methods of\n      CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally\n      administered CJ-12420 to esomeprazole 40mg."
        }, 
        "brief_title": "Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Erosive Esophagitis", 
            "GERD"
        ], 
        "condition_browse": {
            "mesh_term": "Esophagitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged between 20-70\n\n          -  Diagnosed with Erosive Esophagitis by Esophagogastroduodenoscopy (EGD) and classified\n             into LA Grade A to D within 14 days before randomization to treatment\n\n        Exclusion Criteria:\n\n          -  Patients who cannot undergo EGD\n\n          -  Patients diagnosed with irritable bowel syndrome (IBS), inflammatory bowel disease\n             (IBD), or suspected IBS\n\n          -  Patients who took PPIs within 2 weeks prior to study drug administration\n\n          -  Long-term use of nonsteroidal anti-in\ufb02ammatory drugs throughout the study\n\n          -  Clinically significant abnormal laboratory values during screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028663", 
            "org_study_id": "CJ_APA_201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CJ-12420 Amg", 
                    "CJ-12420 Bmg", 
                    "CJ-12420 Cmg"
                ], 
                "description": "Once daily, Oral administration", 
                "intervention_name": "CJ-12420", 
                "intervention_type": "Drug", 
                "other_name": "Undecided"
            }, 
            {
                "arm_group_label": "Esomeprazole 40mg", 
                "description": "Once daily, Oral administration", 
                "intervention_name": "Esomeprazole", 
                "intervention_type": "Drug", 
                "other_name": "Nexium"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "P-CAB", 
            "APA(Acid Pump Antagonist)"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "contact": {
                "last_name": "Nam", 
                "phone": "02-6740-2453"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital and 11 others"
            }, 
            "investigator": {
                "last_name": "Hyun-Chae Jung, MD, Ph.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Double-Blind, Randomized, Dose-finding Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Hyun-Chae Jung, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Cumulative healing rate of erosive esophagitis at 8-week", 
            "safety_issue": "No", 
            "time_frame": "8 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028663"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Healing rate of erosive esophagitis at 4-week", 
            "safety_issue": "No", 
            "time_frame": "4 week"
        }, 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}